← Back to Clinical Trials
Recruiting NCT07119788

NCT07119788 Investigating the Effects of a Haskap Berry Supplement on Cognitive Health

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07119788
Status Recruiting
Phase
Sponsor University of Reading
Condition Cognition
Study Type INTERVENTIONAL
Enrollment 90 participants
Start Date 2025-06-19
Primary Completion 2026-02

Eligibility & Interventions

Sex All sexes
Min Age 50 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
PlaceboPure haskap berry powderVitamin-and mineral-enhanced haskap berry powder

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 90 participants in total. It began in 2025-06-19 with a primary completion date of 2026-02.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to investigate the postprandial (2h) and longer term (4 week) effects of a haskap berry supplement on cognitive, vascular, and metabolic function in healthy ageing adults aged 50+.

Eligibility Criteria

Inclusion Criteria: * 50+ years old * Fruit \& veg intake less than or equal to 4 servings per day * Adequate English language and visual \& auditory acuity to perform the cognitive tasks * Normal BMI for age Exclusion Criteria: * Being diagnosed with psychological or psychiatric disorders * ADHD or dyslexia * Any food allergy or intolerance * Use of medications and dietary supplements that may impact study results * Antibiotic use within the last 3 months * Adherence to vegan or vegetarian diets, or other specific diets that may impact study outcomes * Conditions altering absorption of nutrients (e.g. celiac disease) * Being diagnosed with cardiometabolic disease (including type II diabetes and cardiovascular disease), or suffer from untreated hypertension or thrombosis related disorders * Taking blood thinners

Contact & Investigator

Central Contact

Lynne Bell

✉ l.bell@reading.ac.uk

📞 01189788313

Principal Investigator

Claire Williams

PRINCIPAL INVESTIGATOR

University of Reading

Frequently Asked Questions

Who can join the NCT07119788 clinical trial?

This trial is open to participants of all sexes, aged 50 Years or older, studying Cognition. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07119788 currently recruiting?

Yes, NCT07119788 is actively recruiting participants. Contact the research team at l.bell@reading.ac.uk for enrollment information.

Where is the NCT07119788 trial being conducted?

This trial is being conducted at Reading, United Kingdom.

Who is sponsoring the NCT07119788 clinical trial?

NCT07119788 is sponsored by University of Reading. The principal investigator is Claire Williams at University of Reading. The trial plans to enroll 90 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology